LMB 763

Drug Profile

LMB 763

Alternative Names: LMB-763

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 01 Oct 2016 Phase-II clinical trials in Non-alcoholic steatohepatitis in USA (PO) (NCT02913105)
  • 21 Sep 2016 Novartis Pharmaceuticals plans a phase II trial for Non-alcoholic steatohepatitis in USA, Australia, New Zealand, Jordan and United Kingdom (PO) (NCT02913105)
  • 13 Sep 2016 Preclinical trials in Non-alcoholic steatohepatitis in USA before September 2016 (PO) (NCT02913105)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top